Antibody recognition of cathepsin L1-derived peptides in Fasciola hepatica-infected and/or vaccinated cattle and identification of protective linear B-cell epitopes
Files in This Item:
|corrected version epitope mapping garza-cuartero.pdf||1.08 MB||Adobe PDF||Download|
|Title:||Antibody recognition of cathepsin L1-derived peptides in Fasciola hepatica-infected and/or vaccinated cattle and identification of protective linear B-cell epitopes||Other Titles:||Antibody recognition of cathepsin L1-derived peptides in Fasciola hepatica-infected and/or vaccinated cattle and identification of protective linear epitopes||Authors:||Garza-Cuartero, Laura; Geurden, Thomas; Mahan, Suman M.; Mulcahy, Grace; et al.||Permanent link:||http://hdl.handle.net/10197/11231||Date:||8-Feb-2018||Online since:||2019-12-06T12:24:56Z||Abstract:||Fasciola hepatica infection causes important economic losses in livestock and food industries around the world. In the Republic of Ireland F. hepatica infection has an 76% prevalence in cattle. Due to the increase of anti-helminthic resistance, a vaccine-based approach to control of Fasciolosis is urgently needed. A recombinant version of the cysteine protease cathepsin L1 (rmFhCL1) from F. hepatica has been a vaccine candidate for many years. We have found that vaccination of cattle with this immunodominant antigen has provided protection against infection in some experimental trials, but not in others. Differential epitope recognition between animals could be a source of variable levels of vaccine protection. Therefore, we have characterised for first time linear B-cell epitopes recognised within the FhCL1 protein using sera from F. hepatica-infected and/or vaccinated cattle from two independent trials. Results showed that all F. hepatica infected animals recognised the region 19–31 of FhCL1, which is situated in the N-terminal part of the pro-peptide. Vaccinated animals that showed fluke burden reduction elicited antibodies that bound to the regions 120–137, 145–155, 161–171 of FhCL1, which were not recognised by non-protected animals. This data, together with the high production of specific IgG2 in animals showing vaccine efficacy, suggest important targets for vaccine development.||Funding Details:||European Commission Horizon 2020||Type of material:||Journal Article||Publisher:||Elsevier||Journal:||Vaccine||Volume:||36||Issue:||7||Start page:||958||End page:||968||Copyright (published version):||2018 Elsevier||Keywords:||CHO cells; Animals; Cattle; Cricetulus; Fasciola hepatica; Fascioliasis; Cattle diseases; Peptides; Immunoglobulin G; Vaccines; Heminth antibodies; Helminth antigens; B-lymphocyte epitopes; Vaccination; Epitope mapping; Amino acid sequence; Protein conformation; Molecular models; Cathepsin L||DOI:||10.1016/j.vaccine.2018.01.020||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Veterinary Medicine Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.